High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
A potential AstraZeneca-Bristol Myers deal worth $400 billion would create one of the world’s largest drugmakers and combine major cancer franchises.
By Sabrina Valle and Michael Erman Aug 2 (Reuters) - AstraZeneca Plc and Bristol Myers Squibb held preliminary discussions about a possible combination that would create one of the world's biggest
Aug 2 () - UK drugmaker AstraZeneca has been exploring a deal to combine with U. rival Bristol Myers Squibb, the Financial Times reported on Sunday, citing people familiar with the matter.
Investing.com -- AstraZeneca PLC (NYSE:AZN) and Bristol-Myers Squibb Company (NYSE:BMY) have held talks in recent months about a deal that would combine the companies into one, according to a Financial Times report.
AstraZeneca is plotting a $400bn (£300bn) merger with US rival Bristol Myers Squibb in a deal likely to raise fresh questions over the company’s ties to the UK.
AstraZeneca is plotting a $400bn (£300bn) merger with US rival Bristol Myers Squibb in a deal likely to raise fresh questions over the company’s ties to the UK.
Bristol Myers Squibb's P/E ratio is below the industry average, but you have to take this key fact into consideration before buying it.
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 5.7% year on year to $12.97 billion. The company’s full-year revenue guidance of $49.5 billion at the midpoint came in 4.3% above analysts’ estimates. Its non-GAAP profit of $2.04 per share was 27.7% above analysts’ consensus estimates.
Bristol Myers Squibb (NYSE:BMY) reported second-quarter 2026 revenue of approximately $13 billion, up 5% from a year earlier, as growth in newer products offset declines across its legacy portfolio. The company raised its full-year revenue and adjusted diluted earnings-per-share guidance, citing fir
CorpGov hosted a fireside chat on July 28 from the floor of the New York Stock Exchange with Gabriel Hasson, Global Head of Governance, Shareholder and Activism Advisory, Managing Director at ICR. The in-person interview was joined by Editor-in-Chief John Jannarone and they discussed the back to fundamentals for corporate governance as shareholder activism reaches […] The post Activist Investors Shift Back to Basics: ICR Global Head of Governance Gabriel Hasson, Live at NYSE appeared first on Co
Bristol-Myers Squibb (BMY) delivered a strong Q2 but is experiencing slight delays to the launches o
AbbVie (ABBV) lowered its full-year earnings guidance on Friday to account for the expected dilution
BMY highlights growth portfolio momentum, raises 2026 outlook and advances pipeline priorities as newer medicines drive results.
Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.
Bristol-Myers Squibb (BMY) reported second quarter 2026 results that exceeded Wall Street expectations, with revenue and earnings per share ahead of forecasts and management raising full year guidance for both measures. See our latest analysis for Bristol-Myers Squibb. The strong Q2 surprise has come on top of an already solid run for Bristol-Myers Squibb, with a 1-month share price return of 12.57% and a year to date share price return of 21.32%. Over a longer horizon, total shareholder...
Moby summary of Bristol-Myers Squibb Company's Q2 2026 earnings call
Growth portfolio now drives 60% of revenue as Eliquis surges 21%.
It notched convincing beats on analyst estimates with its second-quarter performance.
Strong revenue growth driven by Eliquis and key growth assets, offset by Opdivo decline and delayed readouts for Milvexian and Cobenfy.
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 5.7% year on year to $12.97 billion. The company’s full-year revenue guidance of $49.5 billion at the midpoint came in 4.3% above analysts’ estimates. Its non-GAAP profit of $2.04 per share was 27.7% above analysts’ consensus estimates.
Bristol Myers Squibb (NYSE:BMY) reported second-quarter results that comfortably exceeded Wall Street expectations, driven by continued strength across its growth portfolio. The pharmaceutical company also raised its full-year 2026 financial outlook, sending its shares more than 1% higher in premarket trading on Thursday.
The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Bristol Myers (BMY) delivered earnings and revenue surprises of +28.30% and +11.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Strong sales of blood thinner Eliquis and newer drugs Camzyos and Reblozyl pushed second-quarter revenue to $12.97 billion, above analyst estimates
Investing.com -- Bristol-Myers Squibb shares rose more than 1% in premarket trading Thursday after the drugmaker posted second-quarter results well ahead of expectations and raised its full-year guidance.
By Michael Erman July 30 (Reuters) - Bristol Myers Squibb raised its full-year revenue and profit forecast on Thursday after reporting second-quarter results that came in well ahead of Wall Street
Bristol Myers Squibb faces declining revenue in its legacy drug portfolio, but new products like Opdivo are offsetting the drop.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
